Please login to the form below

Not currently logged in
Email:
Password:

real-world evidence

This page shows the latest real-world evidence news and features for those working in and with pharma, biotech and healthcare.

Novartis pushes ‘virtual’ clinical trial concept

Novartis pushes ‘virtual’ clinical trial concept

Remote participation in research has the benefit of improving the breadth of participation from wider community and socio-economic backgrounds, while also allowing us to gather more meaningful real-world evidence

Latest news

  • Alex Butler and Matt Baker launch Foundry3 Alex Butler and Matt Baker launch Foundry3

    Foundry. 3. will also be home to the Innovation Foundry, which its founders say is the world’s first independent digital health laboratory. ... The agency is also partnering with a large international clinical trials business to drive innovation in

  • FDA approves AI-based decision support software FDA approves AI-based decision support software

    Real-world evidence was then used to demonstrate the application could notify a neurovascular specialist sooner in cases where a blockage was suspected. .

  • Roche to buy cancer data firm Flatiron for $1.9bn Roche to buy cancer data firm Flatiron for $1.9bn

    Swiss pharma group Roche has beefed up its big data capabilities with a deal to buy Flatiron Health, which focuses on cancer data and real-world evidence platforms. ... The GNS collaboration is “aimed at generating unique insights from a growing volume

  • Pharma is ‘getting lower returns on R&D’ Pharma is ‘getting lower returns on R&D’

    A transformation in the R&D process through the use of technologies such as artificial intelligence, real-world evidence and robotic and cognitive automation could help improve R&D efficiency, along

  • New alliance launches to usher digital therapeutics into the mainstream New alliance launches to usher digital therapeutics into the mainstream

    It is truly a new class of medicine.". Working with partners such as patients, healthcare providers, payers and pharma firms, the DTA will work on real world evidence studies, regulatory frameworks

More from news
Approximately 11 fully matching, plus 56 partially matching documents found.

Latest Intelligence

  • A critical juncture for clinical data management A critical juncture for clinical data management

    Real-world data and evidence, electronic clinical outcome assessments, data from smartphones and other mobile devices, social media community data and electronic health/medical records are examples of the new data

  • Six degrees of participation Six degrees of participation

    Evidence suggests there’s a real appetite for pharma to get involved - especially among patient advocacy groups who recognise the skills and knowledge the industry can offer, ”says Richard Jones, managing ... Pharma has the opportunity to progress

  • The rise of real-world evidence The rise of real-world evidence

    The rise of real-world evidence. Demonstrating efficacy and value requires more than clinical trial data. ... Generating real-world evidence. Companies are stepping up their interest in real-world evidence (RWE) at a time when access to data from outside

  • A quest for innovative solutions A quest for innovative solutions

    Artificial intelligence, real-world evidence and robotic and cognitive automation, to name a few, have the potential to improve study design, physician and patient recruitment and in-trial decision-making, as

  • The tipping point The tipping point

    Then the focus will be ‘why this biosimilar? ’Sharing real-world evidence, as well as HCP and patient experience is crucial for all biosimilars, whether they are first or fourth to ... First and foremost, patients must be reassured the biosimilar is

More from intelligence
Approximately 8 fully matching, plus 40 partially matching documents found.

Latest appointments

  • Remi Gauchoux joins Carenity Remi Gauchoux joins Carenity

    Gauchoux has a 20-year international experience in healthcare and the CRO industries with expertise in late phase and real-world evidence analysis.

  • Dr Ameet Nathwani moves from Novartis to Sanofi Dr Ameet Nathwani moves from Novartis to Sanofi

    Oliver Brandicourt, Sanofi's chief executive officer, said: “ Our industry is experiencing increased pressure to support reimbursement with customized data from real-world evidence, demonstrate ongoing benefit-risk of registered products

  • EMA's Dr Stella Blackburn joins Quintiles EMA's Dr Stella Blackburn joins Quintiles

    Quintiles has appointed Dr Stella Blackburn as vice president and global head of risk management for its real world and late phase research group. ... She said: “ Together with my colleagues at Quintiles, I aim to provide best-in-class solutions for

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • The Heart of the Matter 7: Reality Dawns

    But how can you turn Big Data into high-value Real-World Evidence (RWE)? ... That's when it truly becomes real-world evidence. Everything prior to that is just data.

  • The heart of the matter - Part Three

    The heart of the matter - Part Three. Is pharma doing enough to maximise real world evidence? ... In the modern game of pharma Buzzword Bingo, ‘ real world evidence’ (RWE) is likely to feature prominently on any winning card.

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics